rezpegaldesleukin

Protein / enzyme therapeutic

Also known as NKTR-358, LY3471851

Phase 3underway

Evidence outlook · registrational

Atopic Dermatitis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-05. The sponsor reported topline results of a Phase 2 study on 2026-02-10 (Phase 2b REZOLVE-AD of rezpegaldesleukin: 36-week maintenance period results); that is not the registrational readout.

Also in development:Alopecia Areata · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Atopic Dermatitis
Phase 2 (5)
Alopecia Areata
Atopic Dermatitis
NCT06136741 · Nektar Therapeutics
2023-11-15 – 2026-12-31 · Moderate to Severe Atopic Dermatitis
What this study did
Other / comorbidity
NCT07142252 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2026-05-14 – 2028-05-25 · Type 1 Diabetes Mellitus
What this study did
NCT04677179 · Nektar Therapeutics
2021-03-22 – 2022-08-09 · Colitis, Ulcerative
What this study did
Phase 1 (7)
Atopic Dermatitis
NCT04081350 · Nektar Therapeutics
2019-12-04 – 2022-06-24 · Dermatitis, Atopic
What this study did
Other / comorbidity
NCT05565729 · Nektar Therapeutics
2022-10-05 – 2023-02-23 · Healthy
What this study did
NCT04998487 · Nektar Therapeutics
2021-08-16 – 2022-07-06 · Healthy
What this study did
NCT04119557 · Nektar Therapeutics
2019-11-26 – 2021-07-21 · Psoriasis
What this study did
NCT04133116 · Nektar Therapeutics
2019-10-29 – 2020-03-06 · Healthy
What this study did
NCT03556007 · Nektar Therapeutics
2018-04-18 – 2019-08-29 · Systemic Lupus Erythematosus
What this study did
NCT04380324 · Nektar Therapeutics
2017-03-19 – 2019-01-20 · Healthy
What this study did

Competitive landscape

This drug's own stage for Alopecia Areata: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rezpegaldesleukin: this drugPhase 2Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signal
NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13).
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphaPartial signal
NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow rezpegaldesleukin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
May 2028 (2)
Phase 3Atopic DermatitisRecruiting
Est. primary completion 2028-05 · NCT07690371 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusRecruiting
Est. primary completion 2028-05-25 · NCT07142252 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Atopic DermatitisRecruiting
Est. primary completion 2028-06 · NCT07711418 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 April 2026Topline resultREZOLVE-AA Phase 2b 52-week extension results of rezpegaldesleukin in alopecia areata
Nektar Therapeutics · Source ↗
10 February 2026Topline resultPhase 2b REZOLVE-AD of rezpegaldesleukin: 36-week maintenance period results
Nektar Therapeutics · Source ↗
16 December 2025Topline resultPhase 2b REZOLVE-AA of rezpegaldesleukin narrowly missed its primary endpoint
Nektar Therapeutics · Source ↗
18 September 2025Topline resultREZOLVE-AD Phase 2b results presented at EADV
24 June 2025Topline resultPhase 2b REZOLVE-AD of rezpegaldesleukin met its primary endpoint (16-week induction)
Nektar Therapeutics · Source ↗
February 2023Topline resultPhase 2 lupus study misses its primary endpoint
Nektar Therapeutics · Source ↗